Summary of COVID-19 domperidone studies

1. Rabanal Basalo et al., A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care

173 patient domperidone early treatment RCT: 36% worse recovery (p=0.23) and 15% worse viral clearance (p=0.62).
RCT 173 outpatients with mild-to-moderate COVID-19 showing no significant difference with domperidone versus placebo for viral clearance or symptom recovery.
Oct 2023, Annals of Medicine, https://www.tandfonline.com/doi/full/10.1080/07853890.2023.2268535, https://c19p.org/rabanalbasalo